Author Archives: BNL Staff

BAC vs FNMA stock analysis shows that Fannie Mae could support $150 billion valuation with GSE reform

A side by side comparison of Bank of America (NYSE:BAC) and Fannie Mae (OTCMKTS:FNMA) illustrates just how much value is being eliminated from FNMA stock owners by the Treasury’s unwillingness to rush GSE reform.

Posted in Financial, HADE Platform, Members | Tagged , , , | Leave a comment

Why Merck’s Keytruda is beating Bristol-Myers Opdivo

Bristol-Myers (BMY) Opdivo may have more revenue than Merck’s (MRK) Keytruda, but that’s about it, and it won’t last long.

Posted in HADE Platform, Healthcare & Biotech, Members | Tagged , | Leave a comment

Has BlackBerry Ltd (NASDAQ:BBRY) Stock Finally Turned The Corner, For Good?

Why BBRY stock is soaring higher after earnings, and why BlackBerry Ltd (NASDAQ:BBRY) has not turned the corner.

Posted in Hot Stocks, Members, Technology | Tagged , | Leave a comment

What Netflix (NFLX) Could Learn From Apple’s (AAPL) iPhone X

HADE Platform prediction shows the revenue growth effect of Apple’s (AAPL) new iPhone X, something Netflix (NFLX) should observe with great interest.

Posted in Hot Stocks, Members, Technology, Timely Analysis | Tagged , , , | Leave a comment

Is Kevin Durant Right About Under Armour Shoes? (NYSE:UA) (NYSE:UAA)

Kevin Durant upped his trash talk of Nike competitor Under Armour Inc (NYSE:UA) (NYSE:UAA), and while he makes good points, the timing is bad as Under Armour and UA stock prepares for a meaningful recovery into 2018.

Posted in Members, Retail, Timely Analysis | Tagged , , , , | 1 Comment

Imbruvica vs Keytruda Analysis Shows Why Merck (NYSE:MRK) Stock Is Worth Buying Now

Chart shows that Merck (MRK) is likely significantly undervalued based on performance of Keytruda relative to AbbVie and Johnson & Johnson’s (JNJ) Imbruvica

Posted in HADE Platform, Healthcare & Biotech, Members, Mergers & Acquisitions | Tagged , , , , , | Leave a comment

Is Alexion Pharmaceuticals (NASDAQ:ALXN) Stock A Good Investment?

With Soliris prediction through 2018, we explore whether Alexion Pharmaceuticals (NASDAQ:ALXN) is a good investment opportunity.

Posted in HADE Platform, Healthcare & Biotech, Members | Tagged , | Leave a comment